Literature DB >> 33392349

Incremental Value of FDG PET/CT in Aggressive High Grade B Cell lymphoma with TdT Expression.

Nikita Sampathirao1, Indirani Muthukrishnan1, Ann Kurian2, Jaykanth Amalchandran1, Asra Patel1, Shema Mathew1, Shelley Simon1.   

Abstract

High-grade B-cell lymphoma, an aggressive form of Non-Hodgkin's Lymphoma, is known as a double or triple hit lymphoma based on the presence of MYC and BCL2 without or with BCL6 genetic rearrangements, respectively. It carries a poorer prognosis, compared to other variants of B-cell lymphoma, and its management also differs which requires more intensive chemotherapy in contrast to the routine regimen. Terminal deoxynucleotidyl transferase (TdT), a marker of immaturity is commonly expressed in B-cell lymphoblastic leukemia or lymphoma (B cell ALL) which is absent in mature forms of B-cell lymphoma. The TdT is expressed in high-grade B-cell lymphoma; therefore, it poses a classification and management dilemma, which should be accurately differentiated from B-cell ALL and mandates molecular analysis. Herein, we report a case of a 52-year-old female with biopsy reported as high-grade B-cell lymphoma with TdT expression. She was referred for Fluor-deoxyglucose (FDG) Positron Emission Tomography-Computed Tomography (PET/CT) scan for staging in the absence of molecular analysis for B-cell ALL. It was diagnosed as lymphoma on FDG PET/CT based on its characteristic findings of extensive extranodal involvement of multiple organs with no significant lymphadenopathy establishing the incremental value of FDG PET/CT scan, which helped the clinician to arrive at a conclusion.
© 2021 mums.ac.ir All rights reserved.

Entities:  

Keywords:  Extranodal B-cell lymphoma; FDG PET/CT; TdT expression

Year:  2021        PMID: 33392349      PMCID: PMC7701230          DOI: 10.22038/AOJNMB.2020.48887.1332

Source DB:  PubMed          Journal:  Asia Ocean J Nucl Med Biol        ISSN: 2322-5718


  1 in total

1.  Priority of PET-CT vs CT Thorax for EBUS-TBNA 22G vs 19G: Mesothorax Lymphadenopathy.

Authors:  Paul Zarogoulidis; Haidong Huang; Zhenli Hu; Ning Wu; Jiannan Wang; Dimitris Petridis; Kosmas Tsakiridis; Dimitris Matthaios; Christoforos Kosmidis; Wolfgang Hohenforst-Schmidt; Christos Tolis; Ioannis Boukovinas; Nikolaos Courcoutsakis; George Nikolaidis; Chrysanthi Sardeli; Chong Bai; Chrysanthi Karapantzou
Journal:  J Cancer       Date:  2021-08-05       Impact factor: 4.207

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.